论文部分内容阅读
目的:评价化疗联合CIK细胞免疫疗法对晚期消化道肿瘤的疗效。方法:患者随机分为化疗联合CIK细胞免疫治疗组和单纯化疗组。结果:免疫组患者治疗后出血症状(P=0.015)和体重减轻得到明显改善(P=0.022)。免疫组1 a、2 a生存率分别为46.6%和30.9%,化疗组1 a、2 a生存率分别为20.5%和10.3%。免疫组生存率高于单独组,差异有统计学意义(P=0.028)。结论:化疗联和CIK细胞免疫治疗能够减轻患者化疗不良反应,提高患者免疫功能,延长患者生存期。
Objective: To evaluate the efficacy of chemotherapy combined with CIK cell immunotherapy on advanced gastrointestinal tumors. Methods: Patients were randomly divided into chemotherapy combined CIK cell immunotherapy group and chemotherapy alone group. Results: The bleeding symptoms (P = 0.015) and weight loss in the immunized group were significantly improved after treatment (P = 0.022). The survival rates of 1-year and 2-year in the immunized group were 46.6% and 30.9%, respectively. The 1-year and 2-year survival rates in the chemotherapy group were 20.5% and 10.3%, respectively. The survival rate of the immune group was higher than that of the single group, the difference was statistically significant (P = 0.028). Conclusion: Chemotherapy combined with CIK cell immunotherapy can reduce adverse reactions in patients with chemotherapy, improve immune function and prolong patient survival.